Sangamo Therapeutics to Regain Full Rights to Hemophilia a Gene Therapy Program Following Pfizer’s Decision to Cease Development of Giroctocogene Fitelparvovec
Sangamo Therapeutics將重新獲得對血友病A基因療法項目的完整權利,原因是輝瑞決定停止開發Giroctocogene Fitelparvovec。
Sangamo Therapeutics to Regain Full Rights to Hemophilia a Gene Therapy Program Following Pfizer’s Decision to Cease Development of Giroctocogene Fitelparvovec
Sangamo Therapeutics將重新獲得對血友病A基因療法項目的完整權利,原因是輝瑞決定停止開發Giroctocogene Fitelparvovec。
使用瀏覽器的分享功能,分享給你的好友吧